Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14972951 | 0.82 | MAOB (0.52) | MAPTMAOBALDH1A1DHODHGRM4 | |
| SCHEMBL14972954 | 0.82 | KDM4C (0.47) | MAOBALDH1A1GRM4FLT3 | |
| SCHEMBL14972953 | 0.81 | ALDH1A1 (0.52) | MAPTMAOBALDH1A1DHODHGRM4 | |
| SCHEMBL14973071 | 0.81 | PDE2A (0.39) | MAPTPAX8MAOBNPSR1 | |
| SCHEMBL14973018 | 0.80 | MAOB (0.44) | MAOBALDH1A1DHODHGRM4FLT3 | |
| SCHEMBL14973189 | 0.80 | MAOB (0.42) | MAPTMAOBALDH1A1DHODHGRM4 | |
| SCHEMBL14973102 | 0.79 | HMOX1 (0.38) | MAOBALDH1A1HMOX1GRM4FLT3 | |
| SCHEMBL14973190 | 0.78 | SLC6A5 (0.43) | MAPTMAOBALDH1A1GRM4FLT3 | |
| SCHEMBL14972952 | 0.78 | MAPT (0.52) | MAPTMAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL14973129 | 0.77 | SLC6A5 (0.42) | MAPTMAOBALDH1A1GRM4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | MAPT 129/4885PAX8 4514/4885MAOB 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.